Inhaled insulin (INH, Exubera) is under investigation for preprandial treatment of patients with type 1 and type 2 diabetes (1–3). This dry-powder insulin formulation is delivered by aerosol, permitting the noninvasive administration of rapid-acting insulin (4). Preliminary studies have shown that INH provides reproducible and effective control of glycemia (1,5–7). This randomized controlled tr...

Inhaled Insulin is a recent therapeutic advance for the treatment of Diabetes. It offers a convenient, as well as accepted, alternative to injected Insulin. Subcutaneous administration of Insulin results in the pain, inconvenience, and disruption of lifestyle associated with the injection of Insulin, so there has been increasing demand in the development of Aerosolized Insulin. Recent studies s...

OBJECTIVE This study evaluated pharmacokinetic and glucodynamic responses to AIR inhaled insulin relative to subcutaneous insulin lispro, safety, pulmonary function, and effects of salbutamol coadministration. RESEARCH DESIGN AND METHODS Healthy, mildly asthmatic, and moderately asthmatic subjects (n = 13/group, aged 19-58 years, nonsmoking, and nondiabetic) completed this phase I, open-label...

315 Introduction In recent times, there have been two striking developments in the area of insulin therapy. On the therapy front, insulin therapy especially in type 2 diabetes has become a topic frequently reviewed in literature (Marre, 2000; Korytkowski, 2000). These reviews discuss the role of early insulin initiation in the light of the growing burden of type 2 diabetes coupled with the need...